Compare ARR & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARR | TMDX |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.4B |
| IPO Year | N/A | 2019 |
| Metric | ARR | TMDX |
|---|---|---|
| Price | $17.13 | $68.86 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $18.50 | ★ $148.22 |
| AVG Volume (30 Days) | ★ 3.7M | 1.1M |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 16.69% | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $605,494,000.00 |
| Revenue This Year | N/A | $24.25 |
| Revenue Next Year | N/A | $18.75 |
| P/E Ratio | ★ $27.18 | $344.30 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $13.98 | $60.11 |
| 52 Week High | $19.31 | $156.00 |
| Indicator | ARR | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 51.12 | 42.66 |
| Support Level | $17.04 | $64.90 |
| Resistance Level | $17.24 | $71.14 |
| Average True Range (ATR) | 0.30 | 4.00 |
| MACD | 0.05 | -0.31 |
| Stochastic Oscillator | 56.17 | 25.29 |
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.